- Home
- PSHG vs AEON Comparison
PSHG vs AEON Comparison
Compare PSHG & AEON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
Current Price
$1.92
HOLD
Current Price
$0.98
Company Overview
Basic Information| Metric | PSHG | AEON |
|---|---|---|
| Founded | 2010 | N/A |
| Country | Greece | United States |
| Employees | N/A | 5 |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 24.7M | 26.8M |
| IPO Year | 2010 | N/A |
Fundamental Metrics
Financial Performance| Metric | PSHG | AEON |
|---|---|---|
| Price | $1.92 | $0.98 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $7.20 |
| AVG Volume (30 Days) | ★ 187.2K | 67.0K |
| Earning Date | 03-04-2026 | 03-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $49.57 | N/A |
| Revenue Next Year | $4.76 | N/A |
| P/E Ratio | $1.59 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.31 | $0.38 |
| 52 Week High | $2.58 | $1.45 |
Technical Indicators
Market Signals| Indicator | PSHG | AEON |
|---|---|---|
| Relative Strength Index (RSI) | 44.30 | 42.69 |
| Support Level | $1.77 | $0.94 |
| Resistance Level | $2.06 | $1.12 |
| Average True Range (ATR) | 0.14 | 0.13 |
| MACD | -0.02 | -0.01 |
| Stochastic Oscillator | 29.84 | 9.65 |
Price Performance
Historical Comparison PSHG
AEON
About PSHG Performance Shipping Inc.
Performance Shipping Inc is a provider of shipping transportation services through its ownership of tanker vessels. The company's vessels are employed on time charters with liner companies carrying containerized cargo along various shipping routes. It owns and operates six Aframax tanker vessels.
About AEON AEON Biopharma Inc.
AEON Biopharma Inc is a clinical stage biopharmaceutical company focused on developing of its proprietary botulinum toxin complex ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, with an initial focus on the neurosciences market.